A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Korábbi kezelés

• History of trauma or major surgery within 28 days prior to the first dose of study treatment.
• Prior treatment with an anti-TIGIT antibody.
• Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
• Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
• Discontinued prior immunotherapy for immune related adverse events with a high severity.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Adequate organ and marrow function